Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on EDAP TMS. The associated price target is $14.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight the promising growth trajectory of EDAP TMS’s HIFU business. The company reported a significant year-over-year increase in HIFU sales, with a 77% growth in the second quarter of 2025, suggesting a strong market demand for their products. The placement of a record number of Focal One units and the increased procedure volumes indicate a robust adoption rate, further supported by the purchase of additional systems by major hospitals.
Moreover, the favorable reimbursement updates from the Centers for Medicare & Medicaid Services (CMS) enhance the financial attractiveness of the HIFU treatments, potentially driving further adoption. Additionally, the non-dilutive capital agreement with the European Investment Bank provides EDAP with financial flexibility to expand its commercial operations and explore new indications for its technology. These strategic moves position EDAP well for sustained growth, justifying the Buy rating.
EDAP’s price has also changed moderately for the past six months – from $2.560 to $2.260, which is a -11.72% drop .